CLOs on the Move

G1 Therapeutics

www.g1therapeutics.com

 
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted ...
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.g1therapeutics.com
  • 79 T.W. Alexander Drive 4501 Research Commons Suite 100
    Research Triangle Park, NC USA 27709
  • Phone: 919.213.9835

Executives

Name Title Contact Details
Stillman Hanson
 General Counsel Profile
Chandra Lovejoy
 Vice President of Global Regulatory Affairs Profile
Monica Thomas
 General Counsel Profile
James Hanson
 General Counsel Profile

Similar Companies

Reverie Labs

Engineering next‑generation, brain‑penetrant cancer therapies.

RareCyte

RareCyte is a company focused on characterizing and isolating rare cells from blood.

BioComm Network

BioComm Network is a Laguna Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

C2N Diagnostics

C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.

Segetis

Segetis is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.